Document Detail


Combination of vancomycin and rifampicin for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates.
MedLine Citation:
PMID:  23328960     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: Our study provides data supporting the safety and efficacy of vancomycin-rifampicin combination for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates.
Authors:
Luciana Rodriguez-Guerineau; María Dolors Salvia-Roigés; Marisol León-Lozano; José Manuel Rodríguez-Miguélez; Josep Figueras-Aloy
Publication Detail:
Type:  Journal Article     Date:  2013-01-18
Journal Detail:
Title:  European journal of pediatrics     Volume:  172     ISSN:  1432-1076     ISO Abbreviation:  Eur. J. Pediatr.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-22     Completed Date:  2013-11-18     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  7603873     Medline TA:  Eur J Pediatr     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  693-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / therapeutic use*
Bacteremia / drug therapy*,  microbiology
Coagulase
Drug Therapy, Combination
Female
Humans
Infant, Newborn
Infant, Premature
Male
Retrospective Studies
Rifampin / therapeutic use*
Staphylococcal Infections / drug therapy*
Staphylococcus / drug effects*
Treatment Outcome
Vancomycin / therapeutic use*
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Coagulase; 6Q205EH1VU/Vancomycin; VJT6J7R4TR/Rifampin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Next Document:  Serum macromolecular creatine kinase type 1 as a diagnostic clue in inflammatory bowel disease?